Cascara Ventures
VC Fund
Brussels, Belgium
Cascara Ventures is a VC fund in Brussels focused on Health Care and Medical Device. Cascara Ventures is the new investment fund of Adriaan Hart de Ruijter, experienced entrepreneur and investor in life sciences. Founded in 2016, Cascara invests in the seed stage of companies that apply technology to prevention, therapy and research. Examples are vaccines, medical devices, pharmaceuticals, imaging, software, medical data, robotics,healthcare services, diagnostics and cell therapy.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries Cascara Ventures invests in
Stages Cascara Ventures invests in
Countries Cascara Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Investment Focus
Industry
- Health Care 5 (42%)
- Medical Device 5 (42%)
- Medical 4 (33%)
- Biotechnology 4 (33%)
- Wearables 2 (17%)
Stage
- Series A 5 (42%)
- Seed 3 (25%)
- Series B 2 (17%)
- Series C 1 (8%)
- Venture - Series Unknown 1 (8%)
Country
- Germany 6 (50%)
- Finland 1 (8%)
- The Netherlands 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Adriaan Hart de Ruijter
Managing Director
|
Managing Director | Total investments: 10 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Surgify
|
Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa). | $7.9M / Series A / May 27, 2025 | |
ATRO Medical
|
ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise hascreated the base for the Trammpolin design and the development towards a prototype. | $2.1M / Venture - Series Unknown / Dec 14, 2021 | |
|
Surgify
|
Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa). | $1.1M / Seed / Oct 25, 2017 | |
|
ATRO Medical
|
ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise hascreated the base for the Trammpolin design and the development towards a prototype. | Series A / Jul 17, 2017 | |
microDimensions
|
microDimensions produces innovative software solutions for the processing, analysis, and visualization of biomedical imagery, in particular on a cellular level. Employees of microDimensions continuously strive to create efficient algorithms fulfilling highest quality standards. A particular focus of the company is to offer software products thatcan be integrated into the existing customer workflow seamlessly. | Series A / Jun 16, 2016 | |
Xbird
|
xbird is a provider of software solutions in the healthcare sector, founded in Berlin in 2015. The company uses artificial intelligence to personalize therapies for better results. Especially in diabetes therapy, the algorithms developed by xbird can record the behavior and lifestyle of patients using smartphones and other wearables. In this way,as part of holistic care, health risks can be identified and prevented and long-term treatment can be optimized. | Seed | |
Preventicus
|
Preventicus engineers products for smartphones and smartwatches that obtain health parameters without any extra accessories. It generates data conclusive to a degree previously only obtainable by physicians. Preventicus’ software applications are certified medical devices with an accuracy verified in clinical studies. Its primary product is a classI medical device. Preventicus is the creator of Preventicus Heartbeats, a smart screening solution that identifies atrial fibrillation for stroke prevention, based on technologies that are present in a standard smartphone or smartwatch.Preventicus was founded in 2014 by Thomas Hübner. It is based in Jena, Germany. | Series A | |
Fiagon
|
Fiagon develops clinical navigation systems that reimagine image guidance by improving the function of electromagnetic navigation. Fiagon's systems use electromagnetic tracking matrix algorithms and flexible pointer technology that indicates the position of the instrument used in the CT or MRI image data, allowing physicians to get accurateplanning, improve patient outcomes, and implementation of the operation. | Series C | |
|
microDimensions
|
microDimensions produces innovative software solutions for the processing, analysis, and visualization of biomedical imagery, in particular on a cellular level. Employees of microDimensions continuously strive to create efficient algorithms fulfilling highest quality standards. A particular focus of the company is to offer software products thatcan be integrated into the existing customer workflow seamlessly. | Seed | |
|
Fiagon
|
Fiagon develops clinical navigation systems that reimagine image guidance by improving the function of electromagnetic navigation. Fiagon's systems use electromagnetic tracking matrix algorithms and flexible pointer technology that indicates the position of the instrument used in the CT or MRI image data, allowing physicians to get accurateplanning, improve patient outcomes, and implementation of the operation. | Series B | |
| See all 12 investments → | |||
Co-Investors
DSM Venturing
2 deals together
Thuja Capital
2 deals together
Bayern Kapital
1 deal together
BOM
1 deal together
Butterfly Ventures
1 deal together
European Innovation Council Fund
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Cascara Ventures invest in?
Cascara Ventures invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Seed stage. Most of the 12 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Cascara Ventures?
Public channels for Cascara Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Cascara Ventures?
The team at Cascara Ventures includes Adriaan Hart de Ruijter (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
